| abstract |
The present invention relates to novel HSP27 inhibitors, especially thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to general formula (V), and their use as heat shock proteins The application of HSP27 (HSPB1) selective inhibitory drugs, especially in the treatment of cancer or cystic fibrosis, wherein the inhibitor has particularly favorable activity relative to HSP27 in the range of low micromolar and submicromolar drug concentrations. |